Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in
Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML). This study is based on
the hypothesis that Decitabine delivered after allo-hematopoietic stem cell transplant (HSCT)
in patients with leukemia will enhance disease control by the allogeneic immune system and
lead to a longer disease free survival. The study is designed to provide safety data of
low-dosing in the post-transplant setting.